Valuation: Orthocell Limited

Market Cap 215M 152M 132M 123M 113M 212M 14.49B 1.45B 567M 7.25B 570M 558M 24.2B P/E 2026 *
-19.8x
P/E 2027 * -39.5x
Enterprise Value 172M 122M 106M 98.95M 90.22M 170M 11.62B 1.17B 455M 5.82B 457M 447M 19.41B EV / Sales 2026 *
15.1x
EV / Sales 2027 * 8.61x
Free-Float
83.71%
Yield 2026 *
-
Yield 2027 * -
1 day-2.53%
1 week+5.48%
Current month+5.48%
1 month-3.14%
3 months-7.23%
6 months-16.30%
Current year-29.03%
1 week 0.73
Extreme 0.73
0.82
1 month 0.7
Extreme 0.705
0.82
Current year 0.7
Extreme 0.7
1.16
1 year 0.7
Extreme 0.7
1.6
3 years 0.32
Extreme 0.322
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 20/03/2006
Chief Executive Officer 60 20/03/2006
Director of Finance/CFO - 31/07/2025
Director TitleAgeSince
Director/Board Member 60 20/03/2006
Director/Board Member 60 07/03/2023
Chairman - 31/05/2023
Date Insider Type Main position Quantity % Market Cap.
20/07/26 Buy

Chairman

15,430 0.0057%
17/07/26 Buy 11,573 0.0043%
17/07/26 Buy

Director

16,603 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-2.53%+5.48%-38.89%+97.44% 152M
-1.18%+2.74%+22.92%+9.58% 220B
-0.92%+1.96%-2.51%-20.17% 143B
0.00%+7.37%-16.81%+31.78% 142B
+0.53%+4.85%-49.57%+1.29% 74.91B
-0.53%+3.63%+19.16%+16.56% 53.35B
+0.86%-0.35%-15.84%-16.43% 50.13B
+0.71%+5.62%+24.11%+17.68% 42.16B
-0.63%+3.46%+39.31%+41.78% 40.63B
+2.09%+4.95%-2.04%+3.07% 33.33B
Average +0.10%+4.22%-2.02%+18.26% 80.01B
Weighted average by Cap. -0.09%+3.84%+1.70%+8.05%

Financials

2026 *2027 *
Net sales 11.45M 8.08M 7.01M 6.57M 5.99M 11.27M 772M 77.34M 30.19M 386M 30.35M 29.69M 1.29B 21.55M 15.21M 13.19M 12.36M 11.27M 21.21M 1.45B 146M 56.83M 727M 57.12M 55.88M 2.42B
Net income -12.7M -8.97M -7.77M -7.29M -6.64M -12.5M -856M -85.79M -33.49M -428M -33.66M -32.93M -1.43B -8.55M -6.04M -5.23M -4.9M -4.47M -8.42M -576M -57.75M -22.55M -288M -22.66M -22.17M -962M
Net Debt -42.6M -30.08M -26.07M -24.44M -22.28M -41.93M -2.87B -288M -112M -1.44B -113M -110M -4.79B -29.5M -20.83M -18.05M -16.92M -15.43M -29.03M -1.99B -199M -77.79M -995M -78.19M -76.5M -3.32B
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
14/08/26 A$0.7700 -2.53% 158,944
13/08/26 A$0.7900 -0.63% 87,419
12/08/26 A$0.7950 -0.63% 311,213
11/08/26 A$0.8000 +9.59% 607,089
10/08/26 A$0.7300 0.00% 337,218
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7900AUD
Average target price
1.225AUD
Spread / Average Target
+55.06%

Quarterly revenue - Rate of surprise